WFDC1B Inhibitors
WFDC1B inhibitors are chemical agents designed to interact with and inhibit the activity of a specific protein known as WFDC1B, which belongs to the family of whey acidic protein (WAP) domain-containing proteins. The WAP domain is a conserved segment within these proteins, characterized by a particular sequence of amino acids that form a stable three-dimensional structure. The WFDC1B protein, along with others in the WAP family, is thought to be involved in a variety of cellular processes due to the presence of this domain. Inhibitors targeting WFDC1B are crafted through a detailed understanding of the protein's structure and the molecular interactions that govern its function. By binding to the active or binding sites of the protein, these inhibitors can effectively reduce or block the normal activity of WFDC1B, leading to alterations in the biochemical pathways in which the protein is involved.
The development of WFDC1B inhibitors requires a multidisciplinary approach, combining insights from biochemistry, molecular biology, and structural biology. Studies often begin with the analysis of the gene encoding the protein to understand its expression patterns and regulation. Following gene analysis, the protein itself is studied to determine its structure, particularly the shape and charge distribution of the active site where the inhibitor is intended to bind. Through techniques such as X-ray crystallography or nuclear magnetic resonance (NMR) spectroscopy, researchers can obtain detailed images of the protein at an atomic level. This structural information is crucial for the design of inhibitors, as it allows for the creation of molecules that fit precisely into the protein's active site. These inhibitors are typically small molecules that can be synthesized through chemical means and then tested for their ability to interact with WFDC1B. The specificity and affinity of these inhibitors for WFDC1B are key parameters in their design, ensuring that they will effectively target the intended protein without significant off-target effects on other proteins.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Cyclosporin A is an immunosuppressant that inhibits calcineurin, thereby preventing the activation of NFAT, a transcription factor. Since NFAT regulates immune responses, inhibition of this pathway could indirectly lead to a decrease in WFDC1B expression if WFDC1B is upregulated during immune responses. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is involved in the PI3K/AKT signaling pathway. By inhibiting PI3K, LY294002 prevents AKT activation, potentially reducing the expression of proteins regulated by this pathway, including WFDC1B if it is downstream of PI3K/AKT signaling. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a central protein in the mTOR signaling pathway which regulates cell growth and proliferation. The inhibition of this pathway may decrease the synthesis of proteins involved in cell cycle progression, potentially affecting the expression of WFDC1B if it is related to these cellular processes. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream activators of ERK in the MAPK/ERK pathway. By inhibiting MEK, U0126 can reduce ERK-mediated transcriptional responses, which could lead to reduced expression of WFDC1B if it is a target of this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK can disrupt inflammatory responses and cytokine production. If WFDC1B expression is regulated by stress or inflammatory signals mediated by p38 MAPK, its expression could be reduced by SB203580. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, part of the MAPK signaling pathways. JNK influences transcription factors that regulate apoptosis and inflammatory responses. Inhibition of JNK may decrease the expression of related proteins like WFDC1B if it is part of JNK-mediated cellular stress responses. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can prevent the degradation of IκB, thereby inhibiting NF-κB activation. If WFDC1B expression is regulated by NF-κB, then bortezomib could indirectly reduce its expression by blocking NF-κB-mediated transcription. | ||||||
Chetomin | 1403-36-7 | sc-202535 sc-202535A | 1 mg 5 mg | $186.00 $674.00 | 10 | |
Chetomin disrupts the function of hypoxia-inducible factor 1 (HIF-1), which is crucial for the cellular response to hypoxia. If the expression of WFDC1B is HIF-1 dependent, chetomin can indirectly decrease its levels by preventing HIF-1 from inducing its target genes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is involved in the MAPK/ERK pathway. By blocking MEK, PD98059 can reduce ERK-mediated signaling and potentially decrease the expression of proteins like WFDC1B if they are regulated by this pathway. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
WZ4002 is an inhibitor of EGFR kinase activity, which is important for cell proliferation and survival signals. By inhibiting EGFR, WZ4002 can disrupt signaling pathways that may regulate the expression of proteins such as WFDC1B if they are downstream of EGFR signaling. | ||||||